This story was originally published June 30.
Complete Genomics this week launched a cancer grant program in which it will award four "innovative cancer research projects" with whole-genome sequencing of four matched tumor/normal pairs.
The company will select two entries from the US and two from Europe.
Applications are due by July 29 and winners will be notified after Aug. 12. Further information about the program is available here.
While only four winners will be chosen by the company's internal panel of scientific experts, all applicants will be eligible for a discount on a whole-human genome sequencing project, although the company did not disclose how much of a discount.
Complete Genomics CEO Cliff Reid said in a statement that the projects would help "gain insights into the characterization and possible treatment" of cancer.
Reid has often cited cancer sequencing as a key opportunity for the company and earlier this year disclosed that the firm is developing a "cancer product" to identify differences between tumor and normal cells that it intends to launch some time this year (CSN 3/16/2011).